Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 13, 2024, by Cocrystal Pharma, Inc., a Delaware corporation. The filing serves to announce the Company's results of operations for the fiscal quarter ended September 30, 2024. The Company's common stock trades on The Nasdaq Capital Market under the symbol "COCP."
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued via a press release, which is attached as Exhibit 99.1, but the text of the press release itself is not included in the input data.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The filing references the issuance of a press release containing the quarterly results but does not summarize the specific variances or trends within the report body.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended September 30, 2024, by reviewing Exhibit 99.1 (Press Release) referenced in this filing.
- Confirm the Company's cash position and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are not listed in this summary text.
- Review the full press release for any updates on clinical trial progress or regulatory milestones that may accompany the financial results.
- Note that the filing was signed by James Martin, Chief Financial Officer and Co-Chief Executive Officer.